Pharmaceutical Sector

Strides Arcolab gets USFDA approval for manufacturing unit

Strides Arcolab gets USFDA approval for manufacturing unitStrides Arcolab, one of the leading Indian pharmaceutical company, has informed that the U.S. Food and Drug Administration (USFDA) had approved its oral dosage manufacturing unit in Bangalore.

Following this approval, Strides will be able to export drugs with regulatory approval to the United States.

Recently, the company has secured two abbreviated new drug application (ANDA) approvals for Dexamethasone injection in the strength of 4mg/ml and Dexamethasone Sodium Phosphate injection, in the strength of 10 mg /ml.

Jubilant Organosys inks JV pact with US-based Eli Lilly

Eli Lilly, Jubilant In Joint Venture

One of the well known contract research and manufacturing services Eli Lilly, Jubilant In Joint Venture(CRAMS) pharmaceutical companies in India, Jubilant Organosys has signed up a joint venture agreement with US multinational drug major firm, Eli Lilly in order to offer development services in drugs to each other.

The joint venture, which will start operationalising before the end of this year, is on similar lines as Chorus, Eli Lilly’s early-stage development division. 

Chorus provides fast drug development services to Eli Lilly by roping in external contract research specialists for specific areas of drug development.

Cabinet approves Ranbaxy-Daiichi acquisition deal

The Indian government has finally approved the acquisition of Pharmaceutical Major Ranbaxy Laboratories by Japanese drugmaker Daiichi Sankyo.

Major Breakthrough For Tata Enterprise Advinus Therapeutics

Advinus Therapeutics, a Tata group company, has signed a Drug Discovery Major Breakthrough For Tata Enterprise Advinus TherapeuticsAgreement with Johnson and Johnson subsidiary, Ortho-Mc-Neil-Janssen Pharmaceuticals Inc. 

The company which is only into its third year has other ambitious projects to its credit like an agreement with Merck for two programs in metabolic diseases. Advinus specializes in metabolic ,inflammation and neglected diseases. 

Panacea Biotec’s arm to invest $ 13.1 million in US-based PharmAthene

Pages